Detalhe da pesquisa
1.
Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/- binimetinib or alpelisib.
Br J Cancer
; 124(1): 176-182, 2021 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33204026
2.
Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.
Br J Cancer
; 122(8): 1166-1174, 2020 04.
Artigo
Inglês
| MEDLINE | ID: mdl-32147669
3.
A proof-of-concept study of sequential treatment with the HDAC inhibitor vorinostat following BRAF and MEK inhibitors in BRAFV600mutated melanoma.
Clin Cancer Res
; 2024 May 13.
Artigo
Inglês
| MEDLINE | ID: mdl-38739109
4.
Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.
Cancer Chemother Pharmacol
; 85(5): 917-930, 2020 05.
Artigo
Inglês
| MEDLINE | ID: mdl-32274564